Biotech RadarJobs updated

COMPANY

Leal Therapeutics

HQ: Worcester, MA source · lealtx.com ↗

Clinical Phase 2

We use iterative medicinal chemistry strategies to develop brain-penetrant small molecules including LTX-001 and LTX-007. From company website Source · Oct 13, 2026

Keywords: small molecules small molecule Schizophrenia Amyotrophic Lateral Sclerosis LTX-001 LTX-002

Location: Worcester, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Raises and deals from press releases

Raises announced in these releases: $105M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Raise Series A · $30M source ↗
  2. Trial start Phase 1: A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia source ↗
  3. Trial start Phase 1/Phase 2: A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis source ↗
  4. Raise Series A · $30M source ↗
  5. Raise Undisclosed round · $45M source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT07734493A Study of LTX-001 In Adult Participants With Acute Exacerbation of SchizophreniaPhase 1RecruitingAug 3, 20262027-03 (estimated)
NCT07660614A Study of LTX-002 in Adult Participants With Amyotrophic Lateral SclerosisPhase 1/Phase 2RecruitingApr 29, 20262031-06 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback